-
2 weeks ago | 
ajmc.com | Ryan Haumschild |Eric Tichy
OpinionVideoJune 12, 2025Author(s):,Panelists discuss how policy makers can increase biosimilar adoption through financial incentives, streamlined interchangeability rules, and addressing patent litigation delays, emphasizing that biosimilar savings will ultimately help fund the next wave of health care innovation such as cell and gene therapies.
-
2 weeks ago | 
ajmc.com | Ryan Haumschild |Eric Tichy
OpinionVideoJune 12, 2025Author(s):,Panelists discuss how biosimilar manufacturers can increase uptake by ensuring positive financial outcomes for all stakeholders, maintaining strong patient assistance programs, and working closely with health care providers who significantly influence biosimilar implementation.
-
3 weeks ago | 
ajmc.com | Ryan Haumschild |Eric Tichy
Author(s):,Panelists discuss how health systems can learn from published case examples when implementing biosimilars, noting that biosimilars can create a “win-win” situation where patients see lower costs, payers see lower charges, and providers may experience better margins.
-
3 weeks ago | 
ajmc.com | Ryan Haumschild |Eric Tichy
Author(s):,Panelists discuss how implementing interchangeable biosimilars requires effective communication with providers and patients, emphasizing that educating stakeholders before making changes is essential for successful adoption despite the legal permissions afforded by interchangeability designation.
-
1 month ago | 
ajmc.com | Ryan Haumschild |Eric Tichy
Author(s):,Panelists discuss how biosimilars for adalimumab have faced unique challenges in the prescription benefit space compared with earlier oncology biosimilars, highlighting the importance of interchangeability designation, advance planning, and stakeholder education when implementing biosimilar adoption strategies.
-
Jan 17, 2025 | 
businessandamerica.com | Ryan Haumschild
Video content above is prompted by the following:With several abstracts at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024 studying bispecific therapies in combination with conventional chemotherapy regimens, what factors should clinicians consider when deciding between monotherapy and combination approaches for bispecifics in FL and DLBCL? Do you see combination therapies with bispecifics as more viable in certain subtypes of B-cell lymphoma compared with others?
-
Jan 17, 2025 | 
ajmc.com | Ryan Haumschild
OpinionVideoJanuary 17, 2025Author(s):,Panelists discuss how the clinical implications of emerging Bruton tyrosine kinase inhibitor (BTKi)trials in mantle cell lymphoma (MCL) are addressing unmet needs by providing novel therapeutic options, and explore how the integration of these therapies into current chronic lymphocytic leukemia (CLL) and MCL treatment guidelines could reshape management strategies, with consideration given to factors such as efficacy, safety, and patient access.
-
Jan 15, 2025 | 
businessandamerica.com | Ryan Haumschild
Video content above is prompted by the following:McMichael: In which patients do you treat AA vs use observation? Is there a scoring system that you use? Source link
-
Jan 15, 2025 | 
businessandamerica.com | Ryan Haumschild
Video content above is prompted by the following:Ungar: Which key factors influence your choice of initial therapy for patients with AA? Which drug classes do payers initially require in patients recently diagnosed with AA? Which therapies have the highest success rate? Which therapies have the lowest success rate? Source link
-
Jan 13, 2025 | 
businessandamerica.com | Ryan Haumschild
Video content above is prompted by the following:What is the epidemiology of AA, and can you describe the different forms of AA that you see in your practice? a. Is there a population in which you have seen most commonly have AA occurs more frequently in based on your clinical experience? Source link
